AMENDMENT OF THE CLAIMS:

1. (Currently amended) A dry powder pharmaceutical composition for inhalation therapy comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate, an excipient and a ~~derivatised~~ derivatized carbohydrate in particulate form.

2. (Currently amended) A dry powder pharmaceutical composition according to claim 1 in which salmeterol is present as its 1-hydroxy-2-naphthoate ~~(xinofoate)~~ salt.

3. (Currently amended) A dry powder pharmaceutical composition according to claim 1 ~~or 2~~ in which the ~~derivatised~~ derivatized carbohydrate is a mono or di-saccharide in which at least one hydroxyl group of the carbohydrate group is substituted with a hydrophobic moiety via either ester or ethers linkages.

4. (Currently amended) A dry powder pharmaceutical composition according to ~~any one of claims 1—3~~ claim 1 in which the ~~derivatised~~ derivatized carbohydrate is a carbohydrate selected from fructose, glucose, mannitol, maltose, mannitol, trehalose, cellobiose, lactose and sucrose in which at least one hydroxyl group of said carbohydrate is substituted by a straight or branched hydrocarbon chain comprising up to 20 carbon atoms.

5. (Currently amended) A dry powder pharmaceutical composition according to ~~any one of claims 1—4~~ claim 1 in which the ~~derivatised~~ derivatized carbohydrate is selected from the group consisting of cellobiose octaacetate, sucrose octaacetate, glucose pentacetate, mannitol hexaacetate and trehalose octaacetate.

6. (Currently amended) A dry powder pharmaceutical composition according to claim 1 in which the ~~derivatised~~ derivatized carbohydrate is α-D cellobiose octaacetate.

7. (Currently amended) A dry powder pharmaceutical composition according to ~~any one of claims 1 – 5~~ claim 1 in which the ~~derivatised~~ derivatized carbohydrate is present at a concentration of less than 10% of the total composition.

8. (Currently amended) A dry powder pharmaceutical composition according to ~~any one of claims 1 – 7~~ claim 1 in which the ~~derivatised~~ derivatized carbohydrate has an aerodynamic size in the range 1 - 20 μm.

9. (Currently amended) A dry powder pharmaceutical composition according to ~~any one of claims 1 – 8~~ claim 1 in which one component of the excipient ~~that~~ has a particle size of less than 15μm (the fine excipient component) and another component of the excipient ~~that~~ has a particle size of greater than 20μm but lower than 150μm (the coarse excipient component).

10. (Original) A dry powder pharmaceutical composition according to claim 9 in which the fine and coarse excipient components are both lactose.

11. (Currently amended) A dry powder pharmaceutical composition according to ~~any one of claims 1 – 10~~ claim 1 for use in therapy.

12. (Currently amended) A method of treatment or prophylaxis of respiratory disorders which ~~comprise~~ comprises administering to a patient in need thereof a dry powder pharmaceutical composition according to ~~any one of claims 1 – 10~~ claim 1.

13. (Cancelled) ~~Use of a dry powder pharmaceutical composition according to any one of claims 1 – 10 in the manufacture of a medicament for the treatment of respiratory disorders.~~

14. (Currently amended) An inhalation device containing therein a dry powder pharmaceutical composition according to ~~any one of claims 1 – 10~~ claim 1.

15. (Original) An inhalation device according to claim 14 in which the dry powder pharmaceutical composition is released from a pre-metered unit medicament pack.

16. (Currently amended) A medicament pack for use in an inhalation device which comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable composition according to ~~any one of claims 1 – 10~~ claim 1.

17. (Original) A medicament pack according to claim 16 wherein the strip is sufficiently flexible to be wound into a roll.

18. (Original) A medicament pack according to claim 16 wherein the lid sheet and base sheet have leading end portions which are not sealed to one another.

19. (Original) A medicament pack according to claim 18 wherein at least one of the said leading end portions is constructed to be attached to a winding means.

20. (Original) A medicament pack according to claim 16 wherein the hermetic seal between the base and lid sheets extends over their whole width.

21. (Original) A medicament pack according to claim 16 wherein the lid sheet may be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.

22. (Currently amended) A method of improving stability performance ~~The use of particulate derivatised carbohydrates~~ in dry powder pharmaceutical compositions comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate, said method including the step of including in said composition a particulate derivatized carbohydrate ~~in order to improve stability performance~~.

23. (Currently amended) A method of eliminating or reducing the detrimental effect on fine particle dose experienced during storage of a dry powder pharmaceutical composition comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate, wherein said method comprises the step of including a ~~The use of~~ particulate ~~derivatised~~ derivatized ~~carbohydrates~~ carbohydrate

in said dry powder pharmaceutical compositions ~~comprising salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate in order to eliminate or reduce the detrimental effect on fine particle dose caused on storage of said compositions~~.

24. (Currently amended) The ~~use according to~~ method of claim 22 ~~or 23~~ in which the particulate ~~derivatized~~ derivatized carbohydrate is cellobiose octaacetate.

25. (New) The method of claim 23 in which the particulate derivatized carbohydrate is cellobiose octaacetate.